There are several tests that doctors can use to diagnose and monitor COPD. Let's take a look at what abnormal values for ...

Background: There is controversy about whether therapy with inhaled corticosteroids (ICSs) modifies the natural history of COPD, characterized by an accelerated decline in FEV 1. Methods ...

Japan: A recent study published in Annals of Allergy, Asthma & Immunology has highlighted the potential of the baseline ...

Combining Zephyr and Spiration valve therapy benefited patients with COPD and advanced pulmonary emphysema while imparting a ...

FEV 1: Forced expiratory volume in 1 s ... (total energy expenditure/basal metabolic rate – 24 h). 1 Department of Pulmonary Medicine, University Medical Centre Groningen, University of ...

Trial data also showed improvements in quality of life and lung function, with numerically greater improvements in post-bronchodilator forced expiratory volume in 1 second (FEV 1) and a ...

The FDA has approved Dupixent as an add-on maintenance therapy for adults with inadequately controlled COPD and an eosinophilic phenotype.

and had post bronchodilator forced expiratory volume in 1 second/forced vital capacity ratio (FEV1/FVC) of less than 0.7. Overall, the researchers enrolled 100 patients with COPD (mean [SD] age ...

The US Food and Drug Administration has approved dupilumab (Dupixent) as the first biologic treatment for adults with chronic ...

Posters presented at the CHEST 2024 annual meeting demonstrated air pollution's role in lung impairment and disease, ...

RPL554 produced a clinically and statistically significant improvement in peak forced expiratory volume (FEV1) in one second at four weeks in patients with moderate-to-severe COPD compared with ...

The FDA approved dupilumab (Dupixent) as the first biologic treatment for adults with chronic obstructive pulmonary disease ...